Position in LXRX
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$616,524
+$616,522 QoQ
Shares Held
256,885
Ownership
0.058%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#35
of 149 holders
Holding Since
Mar 2020
26 quarters on record
Voting authority
Sole 24%
Shared 0%
None 76%
Common Shares in LXRX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026RHUMBLINE ADVISERS holds $1,404,724,682 across 329 Biotechnology names. LXRX ranks #164 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
396,380 | $196,893,837 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
157,794 | $98,390,870 | |
| 3 | MRNA |
Moderna, Inc.
|
809,853 | $56,714,005 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
165,579 | $49,844,246 | |
| 5 | INCY |
Incyte Corp
|
428,533 | $48,578,500 | |
| 6 | RVMD |
Revolution Medicines, Inc.
|
226,008 | $42,326,778 | |
| 7 | ROIV |
Roivant Sciences Ltd.
|
1,178,789 | $41,717,342 | |
| 8 | JAZZ |
Jazz Pharmaceuticals plc
|
163,018 | $39,282,447 |
All Filings in LXRX
Export CSV
26 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $616,524 | 256,885 | Shares | Sole | 2026-08-12 | |
| 2026-03-31 | $2 | 0 | Shares | Sole | 2026-05-12 | |
| 2025-12-31 | $2 | 0 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $2 | 0 | Shares | Sole | 2025-11-06 | |
| 2025-06-30 | $0 | 0 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $63,125 | 137,230 | Shares | Sole | 2025-05-29 | |
| 2024-12-31 | $113,331 | 153,151 | Shares | Sole | 2025-05-29 | |
| 2024-09-30 | $229,124 | 145,939 | Shares | Sole | 2024-11-12 | |
| 2024-06-30 | $256,678 | 152,785 | Shares | Sole | 2024-08-01 | |
| 2024-03-31 | $323,628 | 134,845 | Shares | Sole | 2024-05-09 | |
| 2023-12-31 | $199,345 | 130,291 | Shares | Sole | 2024-02-08 | |
| 2023-09-30 | $142,017 | 130,291 | Shares | Sole | 2023-11-09 | |
| 2023-06-30 | $320,020 | 139,747 | Shares | Sole | 2023-08-08 | |
| 2023-03-31 | $303,910 | 125,066 | Shares | Sole | 2023-05-11 | |
| 2022-12-31 | $227,513 | 119,117 | Shares | Sole | 2023-02-14 | |
| 2022-09-30 | $272,148 | 113,395 | Shares | Sole | 2022-11-10 | |
| 2022-06-30 | $181,294 | 97,470 | Shares | Sole | 2022-08-11 | |
| 2022-03-31 | $167,062 | 79,934 | Shares | Sole | 2022-05-12 | |
| 2021-12-31 | $341,440 | 86,660 | Shares | Sole | 2022-02-10 | |
| 2021-09-30 | $403,996 | 83,991 | Shares | Sole | 2021-11-12 | |
| 2021-06-30 | $375,425 | 81,792 | Shares | Sole | 2021-08-05 | |
| 2021-03-31 | $323,307 | 55,078 | Shares | Sole | 2021-05-06 | |
| 2020-12-31 | $193,876 | 56,689 | Shares | Sole | 2021-02-10 | |
| 2020-09-30 | $72,228 | 50,159 | Shares | Sole | 2020-11-12 | |
| 2020-06-30 | $129,772 | 64,886 | Shares | Sole | 2020-08-13 | |
| 2020-03-31 | $110,383 | 56,607 | Shares | Sole | 2020-05-06 | |
| No filing history on record for this holder in this stock. | ||||||